What Unichem Pharmaceuticals does

Unichem Pharmaceuticals is a private, for-profit manufacturer and distributor of label generic pharmaceutical products, headquartered in East Brunswick, New Jersey. Founded in 2005, the company operates with a workforce sized at 11 to 50 employees, placing it firmly in the small-enterprise segment of the US generics market. Publicly disclosed leadership is limited to a single named executive, Scott B. Delaney, who holds the combined role of President and CEO. The firm's operating footprint, customer base, and product mix beyond the broad 'label generic pharmaceutical products' descriptor are not disclosed in the source material.

The company's product portfolio, manufacturing capabilities, packaging lines, and channel strategy are not specified in any available source. There is no disclosure of dosage forms, therapeutic categories, API sourcing arrangements, manufacturing certifications (FDA, cGMP, DEA), or facility locations beyond the East Brunswick headquarters. The company's website at unichemusa.com returned only a verification/loading page during data capture and yielded no substantive content. Likewise, there is no public technology stack, no proprietary platform, and no patent or trademark record disclosed, leaving the technical underpinning of the operation uncharacterized from external signals alone.

The revenue model, pricing structure, contract terms, and customer segmentation are entirely unspecified in the source material. No funding history, M&A activity, partnership, customer logo, geographic expansion, regulatory action, or leadership change beyond the single CEO entry is documented. Ownership, capitalization, and governance are similarly opaque. This produces a material data gap: while the firmographic spine (name, location, sector, founding year, headcount band, CEO) is intact, virtually all commercially and strategically relevant dimensions are blank, and any analytical conclusion beyond confirming the company's basic identity should be treated as preliminary pending first-party disclosure.

Name

Unichem Pharmaceuticals

Website

https://unichemusa.com

Company type

Private

Founded year

2005

Headcount range

11–50 employees

Short description

Unichem Pharmaceuticals is a private US-based manufacturer and distributor of label generic pharmaceutical products, headquartered in East Brunswick, New Jersey. Founded in 2005, it operates with 11 to 50 employees under President and CEO Scott B. Delaney.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Drug distribution
• Label medications
• Pharmaceutical products

Headquarters

HQ city

East Brunswick

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Core offering

Unichem Pharmaceuticals is a manufacturing company that produces and distributes label generic pharmaceutical products. The company formulates and ships generic medications intended for downstream commercial buyers in the pharmaceutical supply chain. Specific product lines, SKUs, or therapeutic categories are not documented in available source material.

Differentiator

Problem solved

Functional benefit

Products and services

• Label generic pharmaceutical products Manufactured label generic pharmaceutical products distributed to downstream buyers in the U.S. pharmaceutical supply chain. Specific SKUs, therapeutic categories, or product-level details are not documented in available source material.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Sun Pharmaceutical Industries: India-based generic manufacturer with a sizeable US presence in finished dosage generics and specialty formulations; overlaps with Unichem in core generic manufacturing and US distribution.
• Aurobindo Pharma USA: US operations of a major India-based generic manufacturer offering an extensive portfolio of generic formulations across therapeutic categories — broader scale, but directly overlapping in product and channel.
• Apotex Corp: Large Canadian-headquartered generic manufacturer with substantial US operations producing finished dosage generics for retail and institutional channels.
• Teva Pharmaceutical Industries: The largest US generic manufacturer, offering the broadest small-molecule generic portfolio and unmatched distribution scale; competes with Unichem across nearly every retail generic category.
• Amneal Pharmaceuticals: US-headquartered specialty and generics manufacturer with a broad small-molecule generics portfolio and integrated distribution; comparable across product, channel, and US customer base.
• Sandoz (Novartis): Global leader in off-patent medicines including generic finished dosage forms, with deep US retail and hospital channel coverage; sets benchmark pricing Unichem must compete against.

Direct peers

• Zydus Pharmaceuticals (USA): US arm of an India-headquartered manufacturer with a broad portfolio of generic finished dosage forms distributed throughout the US market.
• Lannett Company: US-focused, small-to-mid cap generic drug manufacturer with a similar product portfolio of finished dosage generics and a comparable sales channel focus on wholesalers, distributors, and pharmacy customers.
• Heritage Pharmaceuticals (Amneal): Generic pharmaceuticals manufacturer distributing broad-line small-molecule generics to US retailers and institutions — directly comparable in product type, channel, and customer base to Unichem.
• Glenmark Pharmaceuticals USA: US subsidiary of an India-based generic manufacturer producing oral solids and other generic dosage forms distributed through US wholesalers and pharmacy chains.

Market position

Strengths3 records

Weaknesses3 records

Key risks4 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unichem Pharmaceuticals